Bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone (BLEO-CCVPP) in patients with Hodgkin's disease who relapsed after radiotherapy alone: A long-term follow-up study of the Eastern Cooperative Oncology Group (E3481)

Thirty-three evaluable patients with Hodgkin's disease who failed radiother apy were treated on this phase II study with bleomycin, lomustine, cyclopho sphamide, vincristine, procarbazine and prednisone given every 28 days for a minimum of right courses. Twenty-five patients (76%: 95% CI=55.6-87.1%) a chieved a complete remission, the median duration of which cannot yet be de termined. but the probability of remaining in continuous complete remission at 10 years is .64. The median survival from entry on this study for all e valuable patients is 10 years, and 12 patients were alive at the time of th is analysis with a median follow-up for them of 15.5 years. Of the 22 patie nts who died, 11 died of progressive or recurrent Hodgkin's disease and 11 died of other causes including 7 second primary neoplasms and at least one myocardial infarction. Both are now well known late complications of Hodgki n's disease treatment.